What is Kintara Therapeutics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kintara Therapeutics's interest expense for the
three
months ended in Jun. 2024 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kintara Therapeutics's Operating Income for the
three
months ended in Jun. 2024 was $ -2.39 Mil. Kintara Therapeutics's Interest Expense for the
three
months ended in Jun. 2024 was $ 0.00 Mil.
Kintara Therapeutics has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Kintara Therapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintara Therapeutics (NAS:KTRA) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Kintara Therapeutics's Interest Expense for the
three
months ended in Jun. 2024 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Jun. 2024 was $-2.39 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Jun. 2024 was $0.00 Mil.
Kintara Therapeutics's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as
| Kintara Therapeutics had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Kintara Therapeutics Inc has no debt.
Kintara Therapeutics Business Description
Traded in Other Exchanges
N/A
Address
9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Executives
| Robert Hoffman |
director, officer: President and CEO |
ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121 |
| Anthony Scott Praill |
officer: Chief Financial Officer |
2001-889 HOMER STREET, VANCOUVER A1 V6B 5S3 |
| Saiid Zarrabian |
director, officer: Head of Strategic Partnerships |
P.O. BOX 675765, RANCHO SANTA FE CA 92067 |
| Laura L. Johnson |
director |
C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122 |
| Tamara A Seymour |
director |
C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008 |
| Toth Robert Joseph Jr |
director |
543 LOMBARD ST, SAN FRANCISCO CA 94133 |
| Dennis M Brown |
officer: Chief Scientific Officer |
100 SAN MATEO DR, MENLO PARK CA 94025 |
| Keith Murphy |
director |
6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121 |
| John Liatos |
director, officer: SVP, Business Development |
12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
| John K Bell |
director |
38 FALLBROOK LANE RR 33, CAMBRIDGE A6 N3H 4R8 |
| Napoleone Ferrara |
director |
550 FRONT STREET, UNIT 1103, SAN DIEGO CA 92101 |
| Lynda Sarah Cranston |
director |
4316 LOCARNO CRESCENT, VANCOUVER A1 V6R 1G3 |
| Erich Mohr |
director |
8300 GREENSBORO DRIVE, MCLEAN VA 22102 |
| Jeffrey Bacha |
director |
SUITE 3 1545 WEST 14TH AVENUE, VANCOUVER A1 V6J 2J1 |
| William J Garner |
director |
875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010 |
Kintara Therapeutics Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KTRA has been successfully added to your 